Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:6.2.1.1 (ACS)
 78,556 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Propionyl-L-carnitine (PLC) is under development as a therapeutic for the treatment of peripheral artery disease, coronary heart disease and chronic heart failure. Three methods were examined for labelling PLC in its propionyl group with positron-emitting carbon-11 (t12 = 20.3 min), one chemical and two chemoenzymatic. The former was based on the preparation of [11C]propionyl chloride as labelling agent via 11C-carboxylation of ethylmagnesium bromide with cyclotron-produced [11C]carbon dioxide and subsequent chlorination. Reaction of carrier-added [11C]propionyl chloride with L-carnitine in trifluoroacetic acid gave [11C]PLC in 12% radiochemical yield (decay-corrected) from cyclotron-produced [11C]carbon dioxide. However, the radiosynthesis was unsuccessful at the no-carrier-added (NCA) level of specific radioactivity. [11C]Propionate, as a radioactive precursor for chemoenzymatic routes, was prepared via carboxylation of ethylmagnesium bromide with [11C]carbon dioxide and hydrolysis. NCA [11C]PLC was prepared in 68 min in 14% radiochemical yield (decay-corrected) from [11C]propionate via sequential conversions catalysed by acetate kinase, phosphotransacetylase and carnitine acetyltransferase. A superior chemoenzymatic synthesis of NCA [11C]PLC was developed, based on the use of a novel supported Grignard reagent for the synthesis of [11C]propionate and conversions by S-acetyl-CoA synthetase and carnitine acetyltransferase. This gave an overall radiochemical yield of 30-48% (decay-corrected). This synthesis was automated for radiation safety and provides pure NCA [11C]PLC in high radioactivities ready for intravenous administration within 25 min from radionuclide production. The [11C]PLC is suitable for pharmacokinetic studies in human subjects with PET and the elucidation of the fate of the propionyl group of PLC in vivo.
 ...
PMID:Automated chemoenzymatic synthesis of no-carrier-added [carbonyl-11C]propionyl L-carnitine for pharmacokinetic studies. 937 26

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abiraterone acetate, acyline, adalimumab, adenosine triphosphate, AEE-788, AIDSVAX gp120 B/B, AK-602, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, alprazolam, amdoxovir, AMG-162, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminophylline hydrate, anakinra, anecortave acetate, anti-CTLA-4 MAb, APC-8015, aripiprazole, aspirin, atazanavir sulfate, atomoxetine hydrochloride, atorvastatin calcium, atrasentan, AVE-5883, AZD-2171; Betamethasone dipropionate, bevacizumab, bimatoprost, biphasic human insulin (prb), bortezomib, BR-A-657, BRL-55730, budesonide, busulfan; Calcipotriol, calcipotriol/betamethasone dipropionate, calcium folinate, capecitabine, capravirine, carmustine, caspofungin acetate, cefdinir, certolizumab pegol, CG-53135, chlorambucil, ciclesonide, ciclosporin, cisplatin, clofarabine, clopidogrel hydrogensulfate, clozapine, co-trimoxazole, CP-122721, creatine, CY-2301, cyclophosphamide, cypher, cytarabine, cytolin; D0401, darbepoetin alfa, darifenacin hydrobromide, DASB, desipramine hydrochloride, desloratadine, desvenlafaxine succinate, dexamethasone, didanosine, diquafosol tetrasodium, docetaxel, doxorubicin hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecallantide, efalizumab, efavirenz, eletriptan, emtricitabine, enfuvirtide, enoxaparin sodium, estramustine phosphate sodium, etanercept, ethinylestradiol, etonogestrel, etonogestrel/ethinylestradiol, etoposide, exenatide; Famciclovir, fampridine, febuxostat, filgrastim, fludarabine phosphate, fluocinolone acetonide, fluorouracil, fluticasone propionate, fluvastatin sodium, fondaparinux sodium; Gaboxadol, gamma-hydroxybutyrate sodium, gefitinib, gelclair, gemcitabine, gemfibrozil, glibenclamide, glyminox; Haloperidol, heparin sodium, HPV 16/HPV 18 vaccine, human insulin, human insulin; Icatibant, imatinib mesylate, indium 111 (111In) ibritumomab tiuxetan, infliximab, INKP-100, iodine (I131) tositumomab, IoGen, ipratropium bromide, ixabepilone; L-870810, lamivudine, lapatinib, laquinimod, latanoprost, levonorgestrel, licochalcone a, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, lorazepam, lovastatin; Maraviroc, maribavir, matuzumab, MDL-100907, melphalan, methotrexate, methylprednisolone, mitomycin, mitoxantrone hydrochloride, MK-0431, MN-001, MRKAd5 HIV-1 gag/pol/nef, MRKAd5gag, MVA.HIVA, MVA-BN Nef, MVA-Muc1-IL-2, mycophenolate mofetil; Nelfinavir mesilate, nesiritide, NSC-330507; Olanzapine, olmesartan medoxomil, omalizumab, oral insulin, osanetant; PA-457, paclitaxel, paroxetine, paroxetine hydrochloride, PCK-3145, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, perillyl alcohol, pexelizumab, pimecrolimus, pitavastatin calcium, porfiromycin, prasterone, prasugrel, pravastatin sodium, prednisone, pregabalin, prinomastat, PRO-2000, propofol, prostate cancer vaccine; Rasagiline mesilate, rhBMP-2/ACS, rhBMP-2/BCP, rhC1, ribavirin, rilpivirine, ritonavir, rituximab, Ro-26-9228, rosuvastatin calcium, rosuvastatin sodium, rubitecan; Selodenoson, simvastatin, sirolimus, sitaxsentan sodium, sorafenib, SS(dsFv)-PE38, St. John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, TH-9507, thalidomide, tigecycline, timolol maleate, tiotropium bromide, tipifarnib, torcetrapib, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate, varenicline, VEGF-2 gene therapy, venlafaxine hydrochloride, vildagliptin, vincristine sulfate, voriconazole, VRX-496, VX-385; Warfarin sodium; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, zidovudine.
 ...
PMID:Gateways to clinical trials. 1608 22

Pure rutile and rutile-anatase composite TiO(2) nanoparticles have been successfully synthesized via an ionic liquid-assisted method by hydrolysis of titanium tetrachloride in hydrochloric acid. It is found that the phase composition (ratio of rutile to anatase) of the products increases with increasing the content of ionic liquid [Emim]Br (1-ethyl-3-methyl-imidazolium bromide), therefore, TiO(2) nanoparticles with controlled phase compositions can be obtained in high yields. The structural and morphological characterizations of the resulting samples are investigated by means of X-ray powder diffraction (XRD), transmission electron microscopy (TEM), high-resolution TEM (HRTEM), and Brunauer-Emmett-Teller (BET) analysis, and the results indicate that the diameters of the anatase nanoparticles are in the range of 4-6 nm and the well-defined rutile nanorods are about 3-6 nm in diameter and 20-60 nm in length. More importantly, we find that the [Emim](+) ions can serve as capping agents based on their strong interactions with the (110) facets of rutile, and the [Emim]Br favors the formation of the rutile structure with a rod-like shape due to the mutual pi-stacking interactions of imidazole rings. We believe that this method can be developed into a general way to synthesize other metal oxide nanoparticles on a large scale.
ACS Nano 2009 Jan 27
PMID:Ionic liquid-assisted synthesis of large-scale TiO2 nanoparticles with controllable phase by hydrolysis of TiCl4. 1920 57

We address an outstanding issue associated with the biocompatibility of gold nanorods (GNRs), a promising agent for biomedical imaging and theragnostics. GNRs are typically prepared in the presence of cetyltrimethylammonium bromide (CTAB), a cationic surfactant whose rigorous removal is necessary due to its cytotoxicity and membrane-compromising properties. CTAB-stabilized GNRs can be partially purified by treatment with polystyrenesulfonate (PSS), an anionic polyelectrolyte often used as a surrogate peptizing agent, followed by chloroform extraction and ultrafiltration with minimal loss of dispersion stability. However, in vitro cytotoxicity assays of PSS-coated GNRs revealed IC(50) values in the low to submicromolar range, with subsequent studies indicating the source of toxicity to be associated with a persistent PSS-CTAB complex. Further exchange of CTAB-laden PSS with fresh polyelectrolyte greatly improves biocompatibility, to the extent that 85 microg/mL of "CTAB-free" GNRs (the highest level evaluated) has comparable toxicity to a standard phosphate buffer solution. Ironically, PSS is not effective by itself at stabilizing GNRs in CTAB-depleted suspensions: while useful as a detergent for GNR detoxification, it should be replaced by more robust coatings for long-term stability under physiological conditions.
ACS Nano 2008 Dec 23
PMID:Detoxification of gold nanorods by treatment with polystyrenesulfonate. 1920 82

Here we describe the chemiresistive sensing of volatile organic compounds (VOCs) with films of chemically synthesized approximately 4 nm diameter Au and AuAg alloy nanoparticles (NPs) stabilized by a surfactant, tetraoctylammonium bromide (TOABr). The chemiresistive sensing properties were measured over a concentration range of 100 to 0.04% saturation for methanol (MeOH), ethanol (EtOH), 2-propanol (IPA), and toluene (Tol) vapor analytes and compared directly to the chemiresistive sensing properties of films of 1.6 nm diameter hexanethiolate (C6S)-coated Au monolayer-protected clusters (MPCs). Films of TOABr-stabilized Au NPs exhibit the opposite response compared to those of C6S-coated Au MPCs. The details are unclear, but the mechanism likely involves changes in capacitive charging in the film or improved conductive pathways through the Au NPs upon incorporation of VOCs into the film for the former as opposed to the well-known change in electron hopping conductivity for the latter. This leads to a decrease in resistance in the presence of VOCs for TOABr Au as opposed to an increase for C6S Au. The TOABr Au sensors are more sensitive, especially for polar analytes, and have greater long-term stability compared to C6S Au. The limit of detection (LOD) for films of TOABr-coated Au NPs is 3, 2, 12, and 37 ppm for IPA, MeOH, EtOH, and Tol, respectively, as compared to 106, 326, 242, and 48 for C6S Au. Films of TOABr-stabilized AuAg alloy NPs exhibit the same type of response, but the sensitivity decreases dramatically with increasing Ag content, showing that the metal composition of the NPs in the film plays a role in the sensing properties, which has not been well-recognized in the literature.
ACS Nano 2008 Aug
PMID:Chemiresistive sensing of volatile organic compounds with films of surfactant-stabilized gold and gold-silver alloy nanoparticles. 1920 57

Nature has evolved proteins and enzymes to carry out a wide range of sophisticated tasks. Proteins modified with functional polymers possess many desirable physical and chemical properties and have applications in nanobiotechnology. Here we describe multivalent Newkome-type polyamine dendrons that function as synthetic DNA binding domains, which can be conjugated with proteins. These polyamine dendrons employ naturally occurring spermine surface groups to bind DNA with high affinity and are attached onto protein surfaces in a site-specific manner to yield well-defined one-to-one protein-polymer conjugates, where the number of dendrons and their attachment site on the protein surface are precisely known. This precise structure is achieved by using N-maleimido-core dendrons that selectively react via 1,4-conjugate addition with a single free thiol group on the protein surface--either Cys-34 of bovine serum albumin (BSA) or a genetically engineered cysteine mutant of Class II hydrophobin (HFBI). This reaction can be conducted in mild aqueous solutions (pH 7.2-7.4) and at ambient temperature, resulting in BSA- and HFBI-dendron conjugates. The protein-dendron conjugates constitute a specific biosynthetic diblock copolymer and bind DNA with high affinity, as shown by ethidium bromide displacement assay. Importantly, even the low-molecular-weight first-generation polyamine dendron (1 kDa) can bind a large BSA protein (66.4 kDa) to DNA with relatively good affinity. Preliminary gene transfection, cytotoxicity, and self-assembly studies establish the relevance of this methodology for in vitro applications, such as gene therapy and surface patterning. These results encourage further developments in protein-dendron block copolymer-like conjugates and will allow the advance of functional biomimetic nanoscale materials.
ACS Nano 2007 Sep
PMID:Precisely defined protein-polymer conjugates: construction of synthetic DNA binding domains on proteins by using multivalent dendrons. 1920 26

A versatile method for selectively synthesizing single-crystalline rhombic dodecahedral, cubic, and octahedral palladium nanocrystals, as well as their derivatives with varying degrees of edge- and corner-truncation, was reported for the first time. This is also the first report regarding the synthesis of rhombic dodecahedral palladium nanocrystals. All the nanocrystals were readily synthesized by a seed-mediated method with cetyltrimethylammonium bromide as surfactant, KI as additive, and ascorbic acid as reductant. At the same ascorbic acid concentration, a series of palladium nanocrystals with varying shapes were obtained through manipulation of the concentration of KI and the reaction temperature. The formation of different palladium facets were correlated with their growth conditions. In the absence of KI, the 100 palladium facets are favored. In the presence of KI, the concentration of KI and the reaction temperature play an important role on the formation of different palladium facets. The 110 palladium facets are favored at relatively high temperatures and medium KI concentrations. The 111 palladium facets are favored at relatively low temperatures and medium KI concentrations. The 100 palladium facets are favored at either very low or relatively high KI concentrations. These correlations were explained in terms of surface-energy and growth kinetics. These results provide a basis for gaining mechanistic insights into the growth of well-faceted metal nanostructures.
ACS Nano 2010 Apr 27
PMID:Shape-controlled synthesis of single-crystalline palladium nanocrystals. 2030 89

Given the emergence of nanotherapeutics and nanodiagnostics as key tools in today's medicine, it has become of critical importance to define precisely the interactions of nanomaterials with biological systems and to characterize the resulting cellular response. We report here the interactions of microglia and neurons with gold nanoparticles (GNPs) of three morphologies, spheres, rods, and urchins, coated with poly(ethylene glycol) (PEG) or cetyl trimethylammonium bromide (CTAB). Microglia are the resident immune cells of the brain, primarily involved in surveillance, macrophagy, and production of cytokines and trophic factors. Analysis by dark-field microscopy and by two-photon-induced luminescence (TPL) indicates that the exposure of neural cells to GNPs resulted in (i) GNP internalization by both microglial cells and primary hippocampal neurons, as revealed by dark-field microscopy and by two-photon-induced luminescence (TPL), (ii) transient toll-like receptor 2 (TLR-2) up-regulation in the olfactory bulb, after intranasal administration in transgenic mice, in vivo, in real time, and (iii) differential up-regulation in vitro of TLR-2 together with interleukin 1 alpha (IL-1alpha), granulocyte macrophage colony-stimulating factor (GM-CSF) and nitric oxide (NO) in microglia. The study demonstrates that GNP morphology and surface chemistry strongly influence the microglial activation status and suggests that interactions between GNPs and microglia can be differentially regulated by tuning GNP nanogeometry.
ACS Nano 2010 May 25
PMID:Microglial response to gold nanoparticles. 2049 53

Composite materials made up from a pyridinium polymer matrix and silver bromide nanoparticles embedded therein feature excellent antimicrobial properties. Most probably, the antimicrobial activity is related to the membrane-disrupting effect of both the polymer matrix and Ag(+) ions; both may work synergistically. One of the most important applications of antimicrobial materials would be their use as surface coatings for percutaneous (skin-penetrating) catheters, such as central venous catheters (CVCs). These are commonly used in critical care, and serious complications due to bacterial infection occur frequently. This study aimed at examining the possible effects of a highly antimicrobial pyridinium polymer/AgBr composite on the blood coagulation system, i.e., (i) on the coagulation cascade, leading to the formation of thrombin and a fibrin cross-linked network, and (ii) on blood platelets. Evidently, pyridinium/AgBr composites could not qualify as coatings for CVCs if they trigger blood coagulation. Using a highly antimicrobial composite of poly(4-vinylpyridine)-co-poly(4-vinyl-N-hexylpyridinium bromide) (NPVP) and AgBr nanoparticles as a thin adherent surface coating on Tygon elastomer tubes, it was found that contacting blood platelets rapidly acquire a highly activated state, after which they become substantially disrupted. This implies that NPVP/AgBr is by no means blood-compatible. This disqualifies the material for use as a CVC coating. This information, combined with earlier findings on the hemolytic effects (i.e., disruption of contacting red blood cells) of similar materials, implies that this class of antimicrobial materials affects not only bacteria but also mammalian cells. This would render them more useful outside the biomedical field.
ACS Appl Mater Interfaces 2009 Sep
PMID:Disruption and activation of blood platelets in contact with an antimicrobial composite coating consisting of a pyridinium polymer and AgBr nanoparticles. 2035 31

To improve the biocorrosion resistance of stainless steel (SS) and to confer the bactericidal function on its surface for inhibiting bacterial adhesion and biofilm formation, well-defined inorganic-organic hybrid coatings, consisting of the inner compact titanium oxide multilayers and outer dense poly(vinyl-N-hexylpyridinium) brushes, were successfully developed. Nanostructured titanium oxide multilayer coatings were first built up on the SS substrates via the layer-by-layer sol-gel deposition process. The trichlorosilane coupling agent, containing the alkyl halide atom-transfer-radical polymerization (ATRP) initiator, was subsequently immobilized on the titanium oxide coatings for surface-initiated ATRP of 4-vinylpyridine (4VP). The pyridium nitrogen moieties of the covalently immobilized 4VP polymer, or P(4VP), brushes were quaternized with hexyl bromide to produce a high concentration of quaternary ammonium salt on the SS surfaces. The excellent antibacterial efficiency of the grafted polycations, poly(vinyl-N-pyridinium bromide), was revealed by viable cell counts and atomic force microscopy images of the surface. The effectiveness of the hybrid coatings in corrosion protection was verified by the Tafel plot and electrochemical impedance spectroscopy measurements.
ACS Appl Mater Interfaces 2009 Mar
PMID:Inorganic-organic hybrid coatings on stainless steel by layer-by-layer deposition and surface-initiated atom-transfer-radical polymerization for combating biocorrosion. 2035 86


1 2 3 4 5 6 7 8 9 10 Next >>